Sogroya is gaining popularity among endocrinologists in the treatment of patients with growth failure. It's finally time to discuss the dynamics of Novo Nordisk's EPS changes. Earnings per share ...

Novo Nordisk's 2024 earnings exceeded estimates ... thanks to the launch of Sogroya, a once-weekly treatment for growth hormone deficiency. As for blood disorders, sales also grew by 3%, boosted ...

Significant contributors navigating the course of the Sogroya market include Novo Nordisk A/S. This global leader has been instrumental in defining innovative treatment approaches and standards in ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.

Novo Nordisk has become a global sensation with its popular weight loss drugs like Ozempic and Wegovy. On Wednesday, the Danish multinational pharmaceutical company announced that it would begin ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...